Results 1 to 10 of about 11,456 (188)
Pharmacokinetic Interactions between Canagliflozin and Sorafenib or Lenvatinib in Rats
Molecules, 2022 Hepatocellular carcinoma (HCC) and type 2 diabetes mellitus (T2DM) are common clinical conditions, and T2DM is an independent risk factor for HCC. Sorafenib and lenvatinib, two multi-targeted tyrosine kinase inhibitors, are first-line therapies for ...
Yanjun Cui +5 more
doaj +2 more sources
Molecules, 2023 Diabetic foot infection (DFI) is a common complication in diabetes patients, with foot infections being the leading cause of amputations. Staphylococcus aureus is frequently found in diabetic foot infections, of which methicillin-resistant Staphylococcus
Siyao Gu +8 more
doaj +2 more sources
Effects of canagliflozin on weight loss in high-fat diet-induced obese mice. [PDF]
PLoS ONE, 2017 Canagliflozin, an inhibitor of sodium glucose co-transporter (SGLT) 2, has been shown to reduce body weight during the treatment of type 2 diabetes mellitus (T2DM).
Wenjun Ji +8 more
doaj +2 more sources
Effects of mulberry twig alkaloids and canagliflozin in inadequately controlled type 2 diabetes: a randomized controlled study based on flash glucose monitoring [PDF]
Scientific ReportsHerbal medicines hold therapeutic potential for diabetes management. This study compared the efficacy and safety of mulberry twig alkaloids (SZ-A) versus canagliflozin administration in poorly oral-antidiabetic controlled patients with type 2 diabetes ...
Huiqin Li +8 more
doaj +2 more sources
Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes. [PDF]
PLoS ONE, 2014 This randomized, double-blind, placebo-controlled, single and multiple ascending-dose study evaluated the pharmacodynamic effects and safety/tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes ...
Sue Sha +9 more
doaj +3 more sources
Clinical and Experimental Hypertension, 2023 Pulmonary arterial hypertension (PAH) is a disease with a high mortality and few treatment options to prevent the development of pulmonary vessel remodeling, pulmonary vascular resistance, and right ventricular failure.
Luxun Tang +6 more
doaj +1 more source
Cell Death Discovery, 2022 Sodium-glucose cotransporter 2 inhibitors, which are recently introduced as glucose-lowering agents, improve cardiovascular and renal outcomes in patients with diabetes mellitus.
Cheol Ho Park +6 more
doaj +1 more source
Molecular Oncology, 2023 Non‐small cell lung cancer (NSCLC) has a poor prognosis, and effective therapeutic strategies are lacking. The diabetes drug canagliflozin inhibits NSCLC cell proliferation and the mammalian target of rapamycin (mTOR) pathway, which mediates cell growth ...
Olga‐Demetra Biziotis +18 more
doaj +1 more source
Redox Biology, 2020 Recent cardiovascular outcome trials found that sodium-glucose cotransporter-2 (SGLT2) inhibitors reduce cardiovascular disease and mortality in type 2 diabetic patients; however, the underlying mechanisms are not fully known. Since the proliferation and
Ghazaleh Behnammanesh +4 more
doaj +1 more source
Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. [PDF]
PLoS ONE, 2012 BACKGROUND: Canagliflozin is a sodium glucose co-transporter (SGLT) 2 inhibitor in clinical development for the treatment of type 2 diabetes mellitus (T2DM).
Yin Liang +13 more
doaj +1 more source